Impact of Probiotics on Gut Microbiota and Symptoms in Patients with Irritable Bowel Syndrome

Authors

  • Fisal Javed
  • Sofia Naz Zia ud Din Medical University, Karachi, Pakistan
  • Ali Ansari Zia ud Din Medical University, Karachi, Pakistan

DOI:

https://doi.org/10.61919/jhrr.v5i10.1886

Keywords:

Use of multi-strain probiotics significantly improved the symptoms on comparative analysis. No adverse reactions

Abstract

Background: Irritable bowel syndrome (IBS) is a common condition of gut-brain interaction for which the importance of intestinal dysbiosis, low-grade mucosal inflammation, and altered barrier function is being increasingly appreciated in the field of gastroenterology. Even in the absence of pharmacological access to probiotics in the European market by the authors according to the relevant national legislation. Objective: To estimate the influence of multi-strain probiotics on the course of IBS symptoms and gut microbiota parameters for 12 months in comparison to the traditional care. Methods: Prospective analysis of 86 adult patients who fulfilled the criteria for IBS according to the Rome III criteria from December 2023 through December 2024 was performed according to the personal choice of the patients. Re-evaluation of the patients for 12 months was made on the parameters of symptoms of IBS, health-related quality-of-life measures like HRQL, stool frequency outcomes like SFI, and stool consistency outcomes like SCA in the subset of patients on comparative analysis of fecal parameters for gut microbiotic analysis. Mixed regression analysis was made for the outcomes. Results: Use of probiotics significantly reduced the progression of SSI outcome scores on comparative analysis in favor of the treated group compared to the controls. Higher rates achieved success in the treated compared to the controls on comparative analysis. Conclusion: Long-term probiotic use significantly improved the symptoms of the patients on comparative analysis in favor of the treated group. 12 months in the future.

Downloads

Download data is not yet available.

References

A F, E Q, B L, A L, Yuri AS, L S, et al. Efficacy of Prebiotics, Probiotics, and Synbiotics in Irritable Bowel Syndrome and Chronic Idiopathic Constipation: Systematic Review and Me ta-analysis. Am J Gastroenterol.

B L, Y B. Irritable Bowel Syndrome, Gut Microbiota and Probiotics. J Neurogastroenterol Motil.

B R-J, M V, C A-C, Roberto P-G, Javier S. A Review of Microbiota and Irritable Bowel Syndrome: Future in Therapi es. Adv Ther.

D B, M M, W C, P S. The Utility of Probiotics in the Treatment of Irritable Bowel Syndrome : A Systematic Review. Am J Gastroenterol.

G B, C C, F A. Probiotics in irritable bowel syndrome: Where are we? Neurogastroenterol Motil.

G P, J DS, K W. Treating irritable bowel syndrome with probiotics: the evidence. Proc Nutr Soc.

H FD, Stella HR, Ö ÖA, G L. Probiotics in Irritable Bowel Syndrome: An Up-to-Date Systematic Revie w. Nutrients.

H S, K W. Altered gastrointestinal microbiota in irritable bowel syndrome and it s modification by diet: probiotics, prebiotics and the low FODMAP diet. Proc Nutr Soc.

Heng-Li N, Jiaming X. The efficacy and safety of probiotics in patients with irritable bowel syndrome: Evidence based on 35 randomized controlled trials. International Journal of Surgery.

J PM-F, E Q. THE INTESTINAL MICROBIOTA AND THE ROLE OF PROBIOTICS IN IRRITABLE BOWE L SYNDROME: a review. Arq Gastroenterol.

Junyoung Y, W S, O L, Sang PL, K L, D J, et al. Effect of multispecies probiotics on irritable bowel syndrome: A rando mized, double‐blind, placebo‐controlled trial. J Gastroenterol Hepatol.

K H, R D, N AC, A S, Y R, M B, et al. The effect of a multispecies probiotic on microbiota composition in a clinical trial of patients with diarrhea‐predominant irritable bowel s yndrome. Neurogastroenterol Motil.

K K, E M, M R-S, Sinikka K, M R, S J, et al. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbi ota. Aliment Pharmacol Ther.

K W, E Q. Probiotics in the management of irritable bowel syndrome and inflammat ory bowel disease. Curr Opin Gastroenterol.

Kajander K, Hatakka K, Poussa T, FÄRkkilÄ M, Korpela R. A probiotic mixture alleviates symptoms in irritable bowel syndrome pa tients: a controlled 6‐month intervention. Alimentary Pharmacology & Therapeutics.22(5):387-94.

L M, S D. Meta-analysis of probiotics for the treatment of irritable bowel syndr ome. World J Gastroenterol.

L OM, J M, P K, G H, Fangyi L, Ker-Sang C, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology.

Mayer EA, Savidge T, Shulman RJ. Brain–Gut Microbiome Interactions and Functional Bowel Disorders. Gastroenterology.146(6):1500-12.

Mohammad ZA, Sundos FHK. Efficacy and Safety of Probiotics, Prebiotics and Synbiotics in the Tr eatment of Irritable Bowel Syndrome. Sultan Qaboos Univ Med J.

P M, A F, N T, F C, A F-O, L B, et al. The efficacy of probiotics in the treatment of irritable bowel syndrom e: a systematic review. Gut.

R P, Jennifer TL, Yuhong Y, G L, F T, M S, et al. Gut Microbiota in Patients With Irritable Bowel Syndrome-A Systematic Review. Gastroenterology.

S N, E L, T L, Y C, W L, P CT, et al. Effect of probiotic bacteria on the intestinal microbiota in irritable bowel syndrome. J Gastroenterol Hepatol.

T D, S M, S N, M A. Effectiveness of probiotics in irritable bowel syndrome: Updated syste matic review with meta-analysis. World J Gastroenterol.

Y R, T R-K. The Rationale and Clinical Effectiveness of Probiotics in Irritable Bo wel Syndrome. J Clin Gastroenterol.

Downloads

Published

2025-10-31

How to Cite

Fisal Javed, Sofia Naz, & Ali Ansari. (2025). Impact of Probiotics on Gut Microbiota and Symptoms in Patients with Irritable Bowel Syndrome. Journal of Health and Rehabilitation Research, 5(10), e1886. https://doi.org/10.61919/jhrr.v5i10.1886

Issue

Volume 5, Issue 10 (October 2025)

Section

Articles

License

Copyright (c) 2025 Fisal Javed, Sofia Naz, Ali Ansari

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Public Licensing Terms

This work is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). Under this license:

  • You are free to share (copy and redistribute the material in any medium or format) and adapt (remix, transform, and build upon the material) for any purpose, including commercial use.
  • Attribution must be given to the original author(s) and source in a manner that is reasonable and does not imply endorsement.
  • No additional restrictions may be applied that conflict with the terms of this license.

For more details, visit: https://creativecommons.org/licenses/by/4.0/.